Design of Topical Moxifloxacin Mucoadhesive Nanoemulsion for the Management of Ocular Bacterial Infections
Ocular bacterial infections can lead to serious visual disability without proper treatment. Moxifloxacin (MOX) has been approved by the US Food and Drug Administration as a monotherapy for ocular bacterial infections and is available commercially as an ophthalmic solution (0.5% <i>w</i>/<i>v</i>). H...
Salvato in:
| Autori principali: | , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI AG
2022-06-01
|
| Serie: | Pharmaceutics |
| Soggetti: | |
| Accesso online: | https://www.mdpi.com/1999-4923/14/6/1246 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|